Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRM: Terlipressin for HRS-1
NCT02770716Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- Jul 2019
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hepatorenal syndrome type 1 (HRS-1) comparing Terlipressin with Placebo (2 arms). Primary endpoints: Percentage of Participants With Verified HRS Reversal at 15 days and Percentage of Participants Who Were Viable (Per Protocol) for Inclusion in the Primary End Point Analysis at 25 days. Started Jul 2016; status: completed.
02
Drugs
terlipressin
03
Conditions
hepatorenal syndrome type 1 (HRS-1)
Beyond the preview
Go deeper on NCT02770716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770716.